Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation

Abstract

Natalizumab discontinuation therapy was associated with development of new disease activity. Our tapered protocol showed benefits, as patients in the TG experienced less relapses and lower accumulation of MRI lesions compared to those in the IDG.